{"filings":[{"id":1673596,"accession_number":"0001140361-26-028602","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2026-07-16T11:00:46+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insmed reports positive 12-month OLE data for TPIP in PAH; sustained improvement across endpoints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6MWD improved +55.7m (TPIP continued) and +54.1m (placebo crossed) from baseline at Month 12.","NT-proBNP reduced ~60% in both groups; WHO Functional Class I/II achieved in ~80% of patients.","REVEAL Lite 2.0 score improved 2.0 points (TPIP continued) and 1.4 points (placebo crossed); ~65% low-risk.","TPIP well-tolerated with no new safety signals; most common TEAEs: headache (28.6%), cough (15.4%).","Phase 3 PALM-PAH trial initiated; topline Phase 2b results previously reported June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470363,"accession_number":"0001140361-26-021648","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2026-05-15T20:01:27+00:00","items":["5.07"],"status":"ready","headline":"Shareholders elect Anderson and Desjardins as Class II directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anderson received 153.7M for vs. 32.1M withheld; Desjardins 164.4M for vs. 21.4M withheld.","Non-binding say-on-pay for 2025 NEO compensation approved: 162.1M for, 23.7M against, 74.4K abstain.","Ratification of Ernst & Young as auditor for 2026: 190.4M for, 7.0M against, 45.3K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91326,"accession_number":"0001140361-26-019430","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insmed Q1 revenue $306M, BRINSUPRI $207.9M (44% QoQ); reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q1 2026 revenue $306.0M vs $92.8M YoY; BRINSUPRI contributed $207.9M (+44% vs Q4 2025).","Net loss narrowed to $163.6M ($0.76/sh) from $256.6M ($1.42/sh); cash & securities $1.2B.","FY 2026 guidance reaffirmed: BRINSUPRI revenue >=$1B, ARIKAYCE $450-470M.","Phase 3b ENCORE (ARIKAYCE in MAC) met primary and all multiplicity-controlled endpoints; sNDA H2 2026.","BRINSUPRI received UK marketing authorization; Phase 3 TPIP PAH study initiated in April 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":305964000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91325,"accession_number":"0001140361-26-013659","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Insmed's brensocatib fails Phase 2b HS study; program discontinued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint not met: AN count reduction 45.5% (10mg) and 40.3% (40mg) vs 57.1% placebo at Week 16.","Secondary efficacy endpoints also not met; Insmed halts HS development of brensocatib.","Safety consistent with prior studies; no new signals; 40mg dose well tolerated.","Study enrolled 214 patients at 72 sites; 16-week placebo-controlled phase completed.","Topline results will be presented at a future medical congress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101329,"accession_number":"0001140361-26-010651","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Insmed Reports Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE in MAC Lung Disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: change from baseline in Respiratory Symptom Score at Month 13 showed 17.77 vs 14.66 points (p=0.0299).","All multiplicity-controlled secondary culture conversion endpoints met: 87.8% vs 57.0% by Month 6, 84.7% vs 61.3% by Month 12 (p<0.0001).","Durable culture conversion at Month 15: 76.2% vs 47.6% (p<0.0001).","Plans to file sNDA in U.S. and submit data to PMDA in Japan in H2 2026 for potential label expansion.","Safety profile consistent with known ARIKAYCE profile; no new safety signals observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101328,"accession_number":"0001140361-26-006116","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Insmed reports FY2025 revenue $606M (+67% YoY); guides BRINSUPRI to at least $1B in FY2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 total revenues $606.4M (+67% YoY); ARIKAYCE $433.8M (+19%), BRINSUPRI $172.7M since Aug launch.","Guides FY2026 BRINSUPRI revenue ≥$1B, ARIKAYCE $450-470M; net loss $1,276.8M ($6.42/share) vs $913.8M in 2024.","Cash & equivalents ~$1.4B; plans to fund pipeline including ENCORE, CEDAR, TPIP Phase 3, and gene therapy programs.","Director David W.J. McGirr will not stand for re-election at 2026 annual meeting, no disagreement with company."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":606423000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101327,"accession_number":"0001140361-26-000778","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insmed reports BRINSUPRI 2025 revs $172.7M; ARIKAYCE $433.8M; guides 2026 pipeline milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BRINSUPRI total revenues ~$172.7M for 2025 (~$144.6M in Q4 alone); ~4,000 prescribers, ~9,000 new patients in Q4.","ARIKAYCE global revenues ~$433.8M in 2025 (+19% YoY); 2026 guidance $450M-$470M.","Phase 3 ENCORE (ARIKAYCE in MAC lung) topline expected March/April 2026; sNDA planned H2 2026.","Phase 2b CEDAR (brensocatib in HS) topline expected Q2 2026; Phase 3 PALM-ILD (TPIP) initiated.","Additional Phase 3 TPIP studies in PAH, PPF, IPF planned for 2026; IND filings for INS1033, INS1203 expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117695,"accession_number":"0001140361-25-045836","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Insmed brensocatib fails Phase 2b CRSsNP; acquires INS1148 antibody","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b BiRCh study missed primary endpoint: placebo LS mean -2.44, brensocatib 10mg -2.21, 40mg -2.33.","All secondary endpoints also not met; Insmed discontinues CRSsNP program immediately.","Brensocatib well tolerated with no new safety signals; 40 mg dose had 69.9% TEAEs vs 65.3% placebo.","Acquired INS1148 (anti-SCF248 mAb) from Opsidio; plans Phase 2 in interstitial lung disease and asthma.","INS1148 targets only inflammatory c-Kit signaling, sparing homeostatic pathways, potentially first-in-class."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117694,"accession_number":"0001140361-25-042598","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"European Commission approves BRINSUPRI as first treatment for NCFB in EU","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EC approved BRINSUPRI (brensocatib 25 mg) for NCFB patients 12+ years with ≥2 exacerbations in prior 12 months.","First and only approved treatment for non-cystic fibrosis bronchiectasis in the EU; reviewed under accelerated assessment.","Phase 3 ASPEN study showed 19.4% reduction in annual exacerbation rate vs placebo; key secondary endpoints met.","Approval follows positive CHMP opinion on 16 Oct 2025; Insmed plans EU access starting early 2026.","Applications also under review in UK (MHRA) and Japan (PMDA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117693,"accession_number":"0001140361-25-039789","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insmed Q3 revenue $142.3M (+52% YoY); net loss $370M; BRINSUPRI launch $28.1M; raises ARIKAYCE guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARIKAYCE global revenue $114.3M (+22% YoY); 2025 guidance raised to $420M-$430M.","BRINSUPRI (brensocatib) launched post-FDA approval, Q3 revenue $28.1M; EU positive CHMP opinion.","Net loss $370M ($1.75/shr) vs $220.5M ($1.27/shr) YoY, driven by higher R&D and SG&A for launch.","Cash and securities $1.7B; plans continued investment across pipeline (brensocatib, TPIP, gene therapy).","Upcoming catalysts: Ph2b BiRCh data (CRSsNP) by early Jan 2026; CEDAR (HS) data H1 2026; PALM-ILD start Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":342580000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134127,"accession_number":"0001140361-25-030537","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Insmed receives FDA approval for BRINSUPRI (brensocatib), first treatment for NCFB","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved BRINSUPRI 10 mg and 25 mg for non-CF bronchiectasis in adults and children ≥12 years.","Phase 3 ASPEN: 21.1% (10 mg) and 19.4% (25 mg) reduction in annual exacerbation rate vs placebo.","Approximately 500,000 U.S. patients diagnosed with NCFB; first approved therapy for this condition.","BRINSUPRI available by prescription via specialty pharmacy; commercial launches in EU/UK/Japan expected 2026.","Insmed to host investor call today at 12:00 PM ET to discuss the approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134126,"accession_number":"0001140361-25-029343","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insmed Q2 net loss $321.7M ($1.70/sh); ARIKAYCE revenue $107.4M (+19% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARIKAYCE global revenue $107.4M, up 19% vs Q2 2024; US revenue $68.7M (+7.7%).","Net loss $321.7M vs $300.6M a year ago; R&D spend $177.2M, SG&A $154.8M on brensocatib launch prep.","Cash & securities $1.9B; full-year ARIKAYCE revenue guidance reaffirmed at $405-425M.","Brensocatib PDUFA date Aug 12, 2025; Phase 3 TPIP in PH-ILD to start H2 2025.","Completed $823.1M equity offering in June; redeemed $569.5M convertible notes in April/May."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":200238000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150881,"accession_number":"0001140361-25-022375","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Insmed prices $750M common stock offering at $96/share for brensocatib R&D and commercialization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 7,812,500 shares at $96.00; net proceeds ~$716.3M after underwriting discounts.","Underwriters granted 30-day option for up to 1,171,875 additional shares (~$112.5M).","Proceeds to fund brensocatib R&D, pre-commercial/commercial, ARIKAYCE, TPIP, INS1201, and general corporate.","Offering expected to close June 13, 2025; joint book-runners: Goldman Sachs, Leerink, BofA, Jefferies, J.P. Morgan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150880,"accession_number":"0001140361-25-022023","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Insmed TPIP Phase 2b in PAH meets primary endpoint with 35% PVR reduction (p<0.001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Placebo-adjusted PVR reduction 35% (p<0.001); 6MWD improvement 35.5 m (p=0.003); NT-proBNP reduction 60% (p<0.001).","Once-daily TPIP well tolerated; 75% of patients titrated to max dose 640 µg; 90% completed study.","Insmed to engage FDA for Phase 3; PH-ILD Phase 3 by end 2025; PAH Phase 3 early 2026.","Common TEAEs: cough 40.6%, headache 31.9%, fatigue 10.1%; no deaths in study.","95% of completers enrolled in open-label extension (1,280 µg max dose allowed)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150879,"accession_number":"0001140361-25-021810","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Insmed completes redemption of remaining $1.97M 0.75% convertible notes due 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Redeemed $1,965,204.69 principal amount at 100% plus accrued interest on June 6, 2025.","Redemption covers all notes not previously converted; most holders had converted.","Notes originally issued under Indenture dated Jan 2018, supplemented May 2021.","Transaction follows previously announced redemption; no material financial impact expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150878,"accession_number":"0001140361-25-019490","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Insmed shareholders elect Lee and Lewis; approve say-on-pay, auditor, incentive plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Leo Lee (128.8M for) and William H. Lewis (140.7M for) as Class I directors.","Advisory 'say-on-pay' on 2024 NEO compensation passed: 142.3M for, 4.99M against, 86K abstain.","Ratification of Ernst & Young as independent auditor for 2025 approved: 160.95M for, 5.34M against.","Amendment No. 2 to the 2019 Incentive Plan approved: 137.9M for, 9.34M against, 106.5K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150877,"accession_number":"0001140361-25-017858","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insmed Q1 revenue up 23% to $92.8M; net loss widens to $1.42/sh; brensocatib PDUFA Aug 12","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARIKAYCE total revenue $92.8M (+23% YoY); FY2025 guidance reaffirmed $405-425M.","Net loss $256.6M ($1.42/sh) vs $157.1M ($1.06/sh); R&D $152.6M, SG&A $147.5M.","Brensocatib NDA accepted; PDUFA date Aug 12, 2025; EU/UK MAA accepted.","TPIP Phase 2b in PAH completed; topline data expected June 2025; Phase 3 in PH-ILD planned H2 2025.","$569.5M convertible notes redeemed; cash & securities $1.2B as of March 31."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":92823000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150876,"accession_number":"0001140361-25-015301","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Insmed calls all $569.5M of 0.75% Convertible Notes due 2028 for redemption on June 6, 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Company redeems $569.5M aggregate principal of 0.75% Convertible Senior Notes due 2028 on June 6, 2025.","Redemption price equals 100% of principal plus accrued interest (~$1,000.10 per $1,000 note).","Holders may convert notes until 5:00 p.m. ET on June 4, 2025; conversions settled in common stock at 30.7692 shares per $1,000 principal (conversion price ~$32.50).","If all notes converted, up to 17,523,336 shares of common stock would be issued.","Paying agent: Computershare Trust Company; payment through DTC for book-entry notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150874,"accession_number":"0001140361-25-015487","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K/A","filed_at":"2025-04-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Insmed adjusts conversion rate on 0.75% convertible notes; up to 17.8M shares issuable","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Conversion rate increased to 31.2861 shares per $1,000 principal under make-whole provisions due to redemption notice.","New conversion price equivalent to approximately $31.96 per share.","If all Notes converted, aggregate of up to 17,817,715 common shares would be issued.","Adjustment triggered by delivery of redemption notice prior to March 2028 maturity date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150875,"accession_number":"0001140361-25-014376","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Insmed CCO J. Drayton Wise resigns effective immediately for medical reasons; stays as consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["J. Drayton Wise resigned as Chief Commercial Officer effective April 16, 2025, for personal and medical reasons, unrelated to operations.","He will provide consulting services through December 31, 2025, with automatic two three-month extensions unless mutually terminated.","Consulting fee: $30,000/month during initial period; $20,000/month during extensions. Outstanding equity awards continue to vest.","No replacement named; Wise will support transition under a consulting agreement. Options exercisable for 3 months post-service or original 10-year expiry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169813,"accession_number":"0001140361-25-005570","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"FDA will not hold AdComm for Insmed's brensocatib; PDUFA date Aug 12, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA communicated in Day 74 letter no advisory committee meeting is currently planned.","Priority review reaffirmed with PDUFA target action date of August 12, 2025.","NDA for non-CF bronchiectasis is based on data from the Phase 3 ASPEN study.","Brensocatib could be the first approved treatment for bronchiectasis and first DPP1 inhibitor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169812,"accession_number":"0001140361-25-005190","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Insmed reports Q4 ARIKAYCE revenue $104.4M; brensocatib NDA accepted with Priority Review","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2024 ARIKAYCE revenue $363.7M (+19% YoY); Q4 net loss $235.5M ($1.32/share).","Brensocatib NDA for bronchiectasis accepted by FDA with Priority Review; PDUFA date Aug 12, 2025.","Company reiterates FY2025 ARIKAYCE revenue guidance $405M–$425M (11-17% YoY growth).","Cash, equivalents, and marketable securities approx. $1.4B as of Dec 31, 2024.","Director Alfred Altomari will not stand for re-election at 2025 Annual Meeting; no disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":363707000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169811,"accession_number":"0001140361-25-003266","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"FDA grants priority review to Insmed's brensocatib NDA for bronchiectasis; PDUFA Aug 12, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA with Priority Review; target action date August 12, 2025 under PDUFA.","Brensocatib would be first approved treatment for bronchiectasis and first DPP1 inhibitor if approved.","NDA based on Phase 3 ASPEN study meeting primary endpoint of reduced annualized pulmonary exacerbation rate.","Both 10 mg and 25 mg doses also met key secondary endpoints including time to first exacerbation.","Insmed plans EU, UK, Japan submissions in 2025; commercial launches anticipated in 2026, pending approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169810,"accession_number":"0001140361-25-000711","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insmed reports preliminary 2024 ARIKAYCE revenue of $363.7M, sets 2025 guidance of $405-425M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary 2024 ARIKAYCE global net sales of $363.7M, up 19% YoY; 2025 guidance $405-425M (11-17% growth)","Brensocatib NDA for bronchiectasis submitted to FDA in Dec 2024; U.S. launch expected Q3 2025 under priority review","Phase 2 TPIP in PAH fully enrolled (102 patients); topline data now expected mid-2025","ENCORE trial for ARIKAYCE in MAC lung disease enrolled 425 patients (exceeding 400 target); topline Q1 2026","IND cleared for DMD gene therapy INS1201; first patient dosing anticipated H1 2025"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186869,"accession_number":"0001140361-24-047246","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Insmed terminates $500M equity distribution agreement with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Insmed terminated its Sales Agreement with Leerink Partners LLC, effective November 18, 2024.","The agreement had allowed for up to $500 million in common stock sales; no shares were sold since September 30, 2024.","The company incurred no termination penalties as a result of the agreement's termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186868,"accession_number":"0001140361-24-044703","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Insmed Q3 ARIKAYCE revenue $93.4M (+18% YoY); net loss $1.27/sh; adds $150M loan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARIKAYCE global revenue $93.4M in Q3 2024, up 18% YoY; US $66.9M, Japan $21.0M, Europe/RoW $5.6M.","Net loss $220.5M ($1.27/sh) vs $158.9M ($1.11/sh) in Q3 2023; operating loss $213.4M.","NDA for brensocatib in bronchiectasis on track for Q4 2024; potential US launch mid-2025.","Amended Pharmakon loan adds $150M tranche at 9.60% fixed, maturity extends to Sept 2029.","Ended Q3 with ~$1.5B cash; redeemed $225M convertible notes; raised $371M net via ATM."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":259265000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203405,"accession_number":"0001140361-24-036671","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Insmed completes redemption of $198K principal of 1.75% Convertible Notes due 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Redemption completed August 9, 2024; remaining $198,000 principal redeemed for cash at 100% plus accrued interest.","All outstanding Notes either converted or redeemed; no further liabilities under the Notes.","Redemption follows prior announcement and is in accordance with the Indenture and First Supplemental Indenture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203404,"accession_number":"0001140361-24-036279","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insmed Q2 2024 revenue $90.3M (+17% YoY); net loss $300.6M; guides FY $340-360M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARIKAYCE global revenue $90.3M in Q2 2024, up 17% YoY; U.S. $63.8M, Japan $21.1M, Europe $5.4M.","Net loss $300.6M ($1.94/sh) vs $244.8M loss ($1.78/sh) in Q2 2023; includes $103.7M non-cash fair value charge.","Reiterated FY2024 ARIKAYCE revenue guidance $340M-$360M, representing ~15% YoY growth at midpoint.","Completed public offering of 14.5M shares; net proceeds $713.2M. Redeemed $225M convertible notes due 2025.","Plan to file NDA for brensocatib in bronchiectasis in Q4 2024; Phase 3 ASPEN met primary endpoint with statistical significance."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":165840000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203403,"accession_number":"0001140361-24-032333","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insmed reports additional positive ASPEN data: brensocatib 25 mg slows lung function decline in bronchiectasis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brensocatib 25 mg showed significantly less FEV1 decline vs placebo (38 mL vs -62 mL; p=0.0054) at Week 52.","Brensocatib 25 mg also showed nominally significant FVC preservation (75 mL less decline; p<0.0001).","QOL-B Respiratory Symptom Score improved by 3.8 points with 25 mg dose vs placebo (p=0.0004).","Safety profile favorable; common TEAEs included COVID-19, nasopharyngitis, cough, headache.","Insmed plans to file NDA in Q4 2024; potential U.S. launch mid-2025, Europe/Japan H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219801,"accession_number":"0001140361-24-031492","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Insmed calls all $225M convertible notes due 2025; holders can convert to stock at ~$39.16","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["All $225M of 1.75% Convertible Senior Notes due 2025 called for redemption on August 9, 2024.","Redemption price: 100% of principal plus accrued interest (~$1,001.17 per $1,000 principal).","Holders may convert before 5pm ET on Aug 8, 2024; conversion rate = 25.5384 shares per $1,000, equivalent to $39.16/share.","If all converted, up to 5,746,140 shares of common stock will be issued; Company settles conversions in shares.","Paying agent is Computershare Trust Co., N.A.; notes surrenderable through DTC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219800,"accession_number":"0001140361-24-029955","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Insmed-AstraZeneca negotiation for brensocatib in COPD/asthma expires without agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AstraZeneca exercised final option for brensocatib in COPD/asthma on March 8, 2024.","Negotiation period expired June 12, 2024; no agreement reached.","Insmed retains full worldwide rights to brensocatib outside COPD/asthma.","AstraZeneca has no further rights to develop or commercialize brensocatib in any indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219799,"accession_number":"0001140361-24-028710","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insmed to host commercial webinar on June 4 to discuss market outlook for ARIKAYCE, brensocatib, treprostinil palmitil","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Webinar at 8:00 a.m. ET on June 4, 2024, live via investor relations website.","Focus on three programs: ARIKAYCE (amikacin liposome inhalation), brensocatib, and treprostinil palmitil inhalation powder.","Slide presentation furnished as Exhibit 99.1 with title slide only; no specific financial data disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219798,"accession_number":"0001140361-24-028205","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Insmed prices $650M stock offering of 12.6M shares; net ~$713.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 12,621,359 shares at $51.50/share; net proceeds to Insmed of ~$713.9M (incl. option exercise).","Underwriters exercised full 30-day option to purchase an additional 1,893,203 shares.","Proceeds to fund brensocatib R&D and pre-commercialization, ARIKAYCE commercialization, TPIP R&D.","Goldman Sachs, Leerink Partners, and J.P. Morgan are joint book-running managers; Morgan Stanley, Cantor, Stifel co-lead.","Offering expected to close May 31, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219797,"accession_number":"0001140361-24-027535","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Insmed Announces Positive Topline Results from Phase 3 ASPEN Study of Brensocatib in Bronchiectasis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ASPEN Phase 3 met primary endpoint: brensocatib 10mg and 25mg reduced annualized pulmonary exacerbations by 21.1% (p=0.0019) and 19.4% (p=0.0046) vs placebo.","Brensocatib achieved statistical significance on multiple secondary endpoints including prolongation of time to first PE and odds of remaining exacerbation-free.","Insmed plans to file NDA with FDA in Q4 2024; anticipates U.S. launch mid-2025, Europe/Japan launches first half 2026.","If approved, brensocatib would be first approved treatment for bronchiectasis and first DPP1 inhibitor for neutrophil-mediated diseases.","Brensocatib well-tolerated; severe TEAEs occurred in 12.7% (10mg), 11.7% (25mg), and 16.0% (placebo) with lower serious TEAE rates than placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219796,"accession_number":"0001140361-24-025709","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Insmed shareholders elect four Class III directors and approve 2019 Incentive Plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected David R. Brennan, Leo Lee, Carol A. Schafer, Melvin Sharoky as Class III directors until 2027.","Advisory vote on 2023 executive compensation passed: 120.6M for, 8.1M against, 96.8K abstentions.","Ratified Ernst & Young as independent auditor for 2024: 135.5M for, 4.2M against, 61.8K abstentions.","Approved Amendment No. 1 to the 2019 Incentive Plan: 122.2M for, 6.6M against, 56.8K abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219795,"accession_number":"0001140361-24-025047","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Insmed Q1 ARIKAYCE revenue $75.5M (+16%); TPIP PH-ILD shows strong clinical worsening signal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARIKAYCE Q1 revenue $75.5M, up 16% YoY; net loss $157.1M ($1.06/share) vs $159.8M ($1.17) prior year.","TPIP Phase 2 PH-ILD: 79.3% reached max 640µg dose; clinical worsening 10.3% vs 50% placebo (p=0.0164).","TPIP Phase 2 PAH blinded: first 40 patients showed mean PVR reduction 19.9%, 6MWD +43 meters.","Brensocatib ASPEN topline data expected latter part of Q2 2024; 2024 ARIKAYCE guidance $340M-$360M.","Cash $595.7M at March 31, 2024; company plans Phase 3 for TPIP in PH-ILD in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":75500000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239572,"accession_number":"0001140361-24-012513","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"AstraZeneca exercises final option to develop brensocatib in COPD/asthma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AstraZeneca exercised second option under 2016 license to develop brensocatib in COPD or asthma beyond Phase 2b.","Final commercialization terms subject to good faith negotiation; no financial details disclosed.","Insmed retains full rights to brensocatib in all other indications.","Brensocatib is a DPP1 inhibitor for neutrophil-mediated diseases; AstraZeneca already had first option."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239571,"accession_number":"0001140361-24-008937","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["1.01","1.02","2.02","9.01"],"status":"ready","headline":"Insmed Q4 net loss $186M; ARIKAYCE FY rev $305M (+24%), beats guidance; ASPEN data on track Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $83.7M in Q4 2023 (+41% YoY); full-year 2023 revenue $305.2M (+24% YoY), exceeding guidance.","Net loss $186.1M in Q4 ($1.28/share) and $749.6M for FY2023 ($5.34/share); R&D spend $571M in FY2023.","Cash, equivalents and marketable securities $780.4M as of Dec 31, 2023; new $500M ATM agreement with Leerink entered Feb 22, 2024.","ARIKAYCE global revenue guidance for 2024 reiterated at $340M-$360M (15% YoY growth at midpoint).","Topline data from Phase 3 ASPEN study (brensocatib) expected Q2 2024; Phase 2 TPIP PH-ILD data also expected Q2 2024 ahead of ASPEN."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":305208000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239570,"accession_number":"0001140361-24-000836","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insmed reports prelim 2023 ARIKAYCE sales of ~$305.2M; guides 2024 to $340-360M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARIKAYCE 2023 global net sales ~$305.2M, exceeding upper end of guidance, 24% YoY growth.","2024 ARIKAYCE revenue guidance $340-360M (midpoint 15% growth).","Phase 3 ASPEN (brensocatib) topline data expected latter part of Q2 2024; potential U.S. launch mid-2025.","TPIP Phase 2 PH-ILD study enrollment completed (39 patients); topline data expected Q2 2024.","Phase 3 ENCORE (ARIKAYCE label expansion) topline readout expected 2025; FDA feedback received on ARISE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257098,"accession_number":"0001140361-23-049591","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insmed Q3 ARIKAYCE revenue $79.1M (+17% YoY); net loss $158.9M; FY23 guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARIKAYCE global sales $79.1M for Q3, highest quarter since launch; U.S. $59.2M, Japan $16.0M.","Net loss $158.9M ($1.11/share) vs $131.1M ($1.09/share) in Q3 2022; R&D spend $109.1M.","Cash & marketable securities $786M as of Sep 30, 2023, down from $918M at June 30, 2023.","FY2023 ARIKAYCE revenue guidance reiterated at $295M-$305M; ASPEN topline data expected Q2 2024.","ARISE trial met primary endpoint; plans to explore accelerated filing for MAC lung disease label expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":221515000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274423,"accession_number":"0001140361-23-042505","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insmed Phase 3 ARISE study meets primary endpoint; ARIKAYCE shows strong culture conversion in MAC lung disease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARISE validated QOL-B respiratory domain as PRO tool; to be proposed as primary endpoint for ENCORE without modification.","ARIKAYCE arm achieved 78.8% culture conversion at Month 7 vs 47.1% for comparator (p=0.0010).","QOL-B respiratory score improvement trend: 12.24 vs 7.76 (p=0.1073); 43.8% of ARIKAYCE patients exceeded meaningful threshold.","No new safety signals; discontinuation rate 22.9% for ARIKAYCE vs 7.8% for comparator.","Insmed plans to explore accelerated filing for ARIKAYCE in newly infected MAC patients with global regulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274422,"accession_number":"0001140361-23-037767","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insmed Q2 ARIKAYCE rev $77.2M (+18%), raises FY guide $295-305M; net loss $244.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARIKAYCE global revenue $77.2M, 18% YoY growth, highest quarterly sales since launch.","Full-year 2023 ARIKAYCE revenue guidance raised to $295-305M from $285-300M.","Net loss $244.8M ($1.78/sh) vs $95.6M loss in Q2 2022; R&D costs rose due to $76.5M acquisition of Adrestia.","Cash, equivalents, marketable securities $918M as of June 30, down from $999M at March 31.","Upcoming catalysts: ARISE topline data Sept 2023; ASPEN Phase 3 data expected Q2 2024; TPIP interim data H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":142443000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274421,"accession_number":"0001140361-23-033740","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K/A","filed_at":"2023-07-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Insmed sets annual say-on-pay votes after 99.85% shareholder approval","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders voted 99.85% in favor of annual say-on-pay frequency at May 11, 2023 annual meeting.","Board had recommended annual frequency, and company adopted annual basis for future votes.","Next advisory vote on say-on-pay frequency required by 2029 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291694,"accession_number":"0001140361-23-024132","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Insmed shareholders approve incentive plan, elect directors, adopt universal proxy bylaws","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved Amended and Restated 2019 Incentive Plan with 101.6M for, 11.0M against.","Elected Class II directors: E.M. Anderson, C. Desjardins, D.W.J. McGirr (each with ~87-100M for).","Advisory say-on-pay approved (107.7M for, 5.0M against); future votes every one year (112.5M).","Ratified Ernst & Young as auditor for FY2023 (118.0M for).","Bylaws amended to comply with universal proxy rules and set board size by resolution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291693,"accession_number":"0001140361-23-023332","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insmed unveils four new research platforms; targets 6 INDs by 2025; DMD gene therapy trial in 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gene therapy with targeted AAV delivery; DMD clinical trial to start 2023, muscle biopsy data expected H1 2024.","RNA end-joining (REJ) technology targets Stargardt disease; IND submission expected by end of 2024.","Protein deimmunization platform (DbD) using AI to enable redosable gene therapy and therapeutic proteins.","Proprietary algae-based manufacturing platform for AAV capsid production; $500K investment from CureDuchenne Ventures.","Expects at least six IND applications across platforms by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":291692,"accession_number":"0001140361-23-022852","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insmed Q1 revenue up 23% to $65.2M; net loss widens to $159.8M; pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARIKAYCE global revenue $65.2M, up 23% YoY; U.S. net sales $49.1M, Japan $13.2M.","Net loss $159.8M ($1.17/share) vs $94.6M ($0.80) in Q1 2022; R&D spend rose to $127.9M.","Cash and securities $999M at March 31, 2023, down from $1.15B at Dec 31, 2022.","Phase 3 ASPEN enrollment completed (1,700+ patients); topline data expected Q2 2024.","Reaffirmed FY2023 ARIKAYCE revenue guidance $285M-$300M; appointed Makoto Nakamura GM Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":65214000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312462,"accession_number":"0001140361-23-008163","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insmed reports Q4 2022 ARIKAYCE revenue $59.3M, full year $245.4M; net loss $1.21 per share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARIKAYCE global revenue grew 30% in 2022 to $245.4M; Q4 revenue $59.3M, impacted by $7.5M French pricing adjustment.","Net loss for Q4 2022 was $160.1M ($1.21/share) vs $113.0M ($0.95/share) in Q4 2021; full year net loss $481.5M ($3.91/share).","Phase 3 ASPEN trial of brensocatib in bronchiectasis completed adult patient screening; topline data expected Q2 2024.","Company guides 2023 ARIKAYCE global revenue $285-300M; cash position $1.15B as of Dec 31, 2022.","ARISE study topline data expected Q3 2023; ENCORE enrollment by end 2023; early-stage research update May 8, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":245358000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312461,"accession_number":"0001140361-23-000743","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insmed updates pipeline: ARIKAYCE 2023 rev guidance $285-300M; brensocatib CF data positive","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARIYACE global revenue 2022 up ~30% YoY; 2023 guidance $285-300M.","Phase 2 brensocatib in CF showed dose-dependent NSP inhibition; 65 mg cohort not needed.","Phase 3 ASPEN (bronchiectasis) blended blinded event rate 1.12-1.15 events/patient/year; enrollment on track for Q1 2023.","Post-marketing ARISE trial had 15% treatment discontinuation rate, less than half of pivotal CONVERT.","Early-stage pillars target musculoskeletal, CNS, ocular, rheumatologic; first IND expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330995,"accession_number":"0001140361-22-038593","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Insmed Q3 revenue $67.7M (+45% YoY); net loss $1.09/share; secures $775M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARIKAYCE total revenue of $67.7M: $49.5M U.S., $14.5M Japan, $3.7M Europe/RoW.","Net loss of $131.1M ($1.09 per share) vs $112.7M ($0.96) in Q3 2021.","Cash and marketable securities $513.3M; strategic financings added $775M gross proceeds.","Full-year 2022 ARIKAYCE revenue expected to grow at least 30% YoY.","Phase 3 ASPEN (brensocatib) enrollment on track; topline data expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":186058000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330994,"accession_number":"0001140361-22-037955","cik":1104506,"company_name":"INSMED Inc","ticker":"INSM","form_type":"8-K","filed_at":"2022-10-20T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Insmed raises $775M via term loan, royalty deal, and equity offering to fund pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$350M senior secured term loan from Pharmakon Advisors, maturing Oct 2027, at SOFR+7.75% (floor 2.5%).","$150M synthetic royalty deal with OrbiMed: 4-4.5% of ARIKAYCE sales + 0.75% of brensocatib sales, capped at 1.8-1.9x.","$275M equity offering: 13.75M shares at $20.00; closing expected Oct 21, 2022.","Pro forma cash and marketable securities ~$1.3B; proceeds to fund ARIKAYCE commercial launch, brensocatib readiness, and R&D.","Term loan and royalty financing closed Oct 19, 2022; equity underwriting with J.P. Morgan and SVB Securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":23062461970.54101,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-10-20T23:59:59+00:00|330994"}